Compare Sanofi SA (SNY) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Wix.Com Ltd — how do they compare? Sanofi SA trades at $42.96 (market cap $103.41B), while Wix.Com Ltd trades at $74.3 (market cap $3.11B). The key difference: Sanofi SA is far larger — about 33.3× Wix.Com Ltd's market cap, and Sanofi SA pays a 5.65% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| SNY | WIX | |
|---|---|---|
Market Cap | $103.41B | $3.11B |
Sector | Health | Technology |
52-Week High | $52.34 | $184.24 |
52-Week Low | $41.33 | $40.43 |
Enterprise Value | $123.44B | $4.18B |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
WIX trades at $72.72, down 4.58% amid technical bearish signals and multiple securities class action lawsuits. The company shows revenue growth to $1.99B in 2025 but faces profitability challenges with a negative net income margin of -8.19%. Recent earnings were mixed with Q1 2026 missing expectations while Q2 2026 beat estimates. Cash flow trends show operational strength but significant investing outflows.
Analyst consensus remains positive with 63% buy ratings and $73.36 price target, but legal risks and competitive pressures create headwinds. The stock presents a high-risk opportunity with potential upside if legal issues resolve and AI product execution improves, though current technical weakness suggests caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
